Dear Reader,
After analyzing over 3,000 stocks and a staggering 40,169 data points...
...my team recommends buying one specific stock today.
I explain why — and reveal the ticker for free — right here:
NYSE: ????...
But here's what will surprise you...
According to our research, this is one stock we believe Warren Buffett himself would buy today—if he could.
You see, after more than two decades of research...
...and thanks to a distinguished professor who has advised the FBI, the Pentagon, and Wall Street's biggest hedge funds...
Buffett's oldest and most profitable strategy has finally been figured out.
And right now, it's flashing stronger than ever before on a very specific set of stocks.
At the top of that list is NYSE: ????...
...and it's why we're urging all our readers to review the presentation we've put together that explains why.
If this research is correct—and it seems to be—we could be headed into an unprecedented time in the markets.
A fundamental shift in the way companies operate will see massive gains... and massive losses.
However, as you'll see, according to our research — which the likes of BlackRock, Fidelity and Goldman Sachs pay thousands to access — following Buffett's strategy allows you to make money no matter which way the market is going...
Up. Down. Sideways...
This has been proven to work in all markets.
I urge you to see for yourself what it's all about...
Click here to take a look — and get the ticker for free.
Best wishes,
Rob Spivey
Research Director, Altimetry
P.S. If you want to know the real reason why Buffett finally chose to step down as the CEO of Berkshire this year — you need to see this now.
Why 2 Small Biotechs May Hold the Key to New Cancer Treatments
Submitted by Nathan Reiff. Article Published: 3/12/2026.
Key Points
- Iovance and ImmunityBio each have a leading oncology product that has helped to massively boost sales and share prices in recent quarters.
- Despite major gains in recent trading, IOVA and IBRX shares still have at least 70% in upside potential going forward, according to analysts.
- Profitability remains a concern for both companies, even as sales of their top cancer drugs have surged.
- Special Report: [Sponsorship-Ad-6-Format3]
Cancer remains one of the greatest medical challenges for biotechnology firms, even as the oncology medicine market is expected to surge to $366 billion in the next eight years. Companies often take a niche approach, developing medicines that target specific cancers with dedicated mechanisms. Fortunately, several promising treatments have shown significant potential—and with that comes the possibility of substantial sales.
Two smaller biotech companies are experiencing notable share-price momentum thanks to their leading oncology medicines. Beyond therapeutic potential, these drugs could help the firms move beyond penny-stock or otherwise unstable status and toward long-term profitability. In both cases, meaningful challenges remain, making these typical biotech investments high-risk ventures that also offer the potential for outsized rewards for investors willing to take a chance.
Iovance's Powerful Cancer Drug Is Growing, But Production Challenges Are a Hurdle
They don't want you reading this (Ad)
In 1934, the government executed a legal maneuver that transferred billions in wealth overnight—most Americans had no idea it was coming, a small group who saw it early walked away wealthy, and everyone else paid for it. Trump has the same legal authority today, advisors close to the administration believe he's considering using it, and if he does, the transfer happens fast with the window to be on the right side of it already closing.
Get the free report on how to position yourself nowIovance Biotherapeutics Inc. (NASDAQ: IOVA) defied market trends in early March, surging nearly 37% in a week when the S&P 500 slipped about 1%. That rally added to IOVA's year-to-date performance, which has more than doubled. Still, with a consensus price target of $8.88, Wall Street appears to expect more—that target implies roughly 71% upside from current levels.
The primary catalyst for Iovance's recent gains is Amtagvi, a T-cell immunotherapy for certain types of melanoma.
Amtagvi has been approved in the United States for melanoma since 2024 and is gaining traction, with additional approvals likely in the E.U., U.K., and elsewhere. When administered with Proleukin, the company's IL-2 immunotherapy, management believes Amtagvi could reach more than $1 billion in peak U.S. sales.
Its real upside may lie outside melanoma: Amtagvi received FDA Fast Track designation for non-small cell lung cancer and may prove effective against other tumor types.
Some of Iovance's outperformance this year also reflects its Q4 2025 earnings report, issued in late February, in which the company posted a narrower-than-expected loss per share and reported $5 million in revenue. For the full year, revenue rose about 30% year-over-year.
Iovance remains a small-cap biotech (roughly $2 billion) and is still viewed cautiously by analysts—about half of its roughly dozen ratings are either Hold or Sell. Risks are significant: Amtagvi is a personalized, costly, and complex therapy to manufacture, and that production challenge could constrain profitability even as demand grows.
Massive Sales Growth for ImmunityBio's Bladder Cancer Drug
ImmunityBio Inc. (NASDAQ: IBRX) fell about 20% in March, but its year-to-date performance dwarfs Iovance's. IBRX shares are up nearly 300% in 2026 alone, and analysts remain optimistic—the consensus price target is $13.60, roughly 70% above the stock's current price even after the recent run-up.
ImmunityBio's primary growth driver is Anktiva, a treatment for specific types of bladder cancer. In February, shares jumped after the European regulator granted the drug conditional marketing authorization—the latest in a series of approvals worldwide.
Anktiva is already driving revenue: the drug generated $113 million in sales last year, a roughly 700% year-over-year increase.
Like Amtagvi, Anktiva may have potential in other cancer types, and ImmunityBio is actively exploring additional indications.
Despite the dramatic gains, IBRX remains speculative and risky. The company posted a sizable full-year net loss of $351 million for 2025 as R&D expenses continued to climb. Still, Wall Street sentiment is comparatively bullish: six of seven analysts rate the shares a Buy or equivalent.
Both Iovance and ImmunityBio illustrate the risk-reward dynamics common in small-cap oncology biotech: compelling clinical assets and rapid revenue growth on one hand, and manufacturing complexity, heavy losses, and execution risk on the other. Investors should weigh those factors carefully and perform their own due diligence before making investment decisions.
2 Bad News Buys: Why Palo Alto and Zscaler Are Screaming Deals
Submitted by Thomas Hughes. Article Published: 3/2/2026.
Key Points
- Palo Alto Networks and Zscaler have sold off sharply from their peaks, pushing technicals and valuations to levels that historically foreshadow rebounds.
- Both companies lead cybersecurity with unified, platform-based approaches that deliver industry-leading margins and above-sector revenue growth.
- Institutional buying has overtaken selling since late 2025, and short-covering is underway in both stocks.
- Special Report: [Sponsorship-Ad-6-Format3]
Down as much as 55% from peak to trough and more than 20% year-to-date in 2026, it may be time to buy cybersecurity stocks such as Palo Alto Networks (NASDAQ: PANW) and Zscaler (NASDAQ: ZS). Although valuation concerns have weighed on this sector and may persist, both companies are trading near long-term lows and appear unlikely to decline materially further.
Their growth trajectories remain robust, and long-term forecasts likely understate their advantages in a world of accelerating digitization, broader adoption of digital services, tighter regulation, and AI. While AI improves efficiency and automation for enterprises, it also empowers cybercriminals—raising demand for advanced security solutions.
They don't want you reading this (Ad)
In 1934, the government executed a legal maneuver that transferred billions in wealth overnight—most Americans had no idea it was coming, a small group who saw it early walked away wealthy, and everyone else paid for it. Trump has the same legal authority today, advisors close to the administration believe he's considering using it, and if he does, the transfer happens fast with the window to be on the right side of it already closing.
Get the free report on how to position yourself nowPalo Alto Networks and Zscaler are well-positioned within the industry. Their unified approaches deliver comprehensive security in a highly fragmented market, enabling vendor consolidation, stronger performance, improved threat detection/prevention/mitigation/recovery, scale, and margin expansion.
They offer industry-leading gross and profit margins, with gross margins in the 70%–80% range versus legacy, hardware-based providers. Palo Alto, specifically, markets more than 20 products across cloud, networking, and systems security, while Zscaler is widely regarded as the leader in cloud-native, zero-trust architecture.
Oversold and Ready to Rebound, Palo Alto Networks and Zscaler Are Accumulated
Technical charts show oversold conditions and a strong capacity to rebound. Monthly charts, which reflect ultra-long-term secular trends, sit at long-term lows with stochastic oscillators near historical troughs—conditions that often precede a rebound. Price action is also resting on key support levels.
Weekly charts tell a similar story. Zscaler's stochastic has been flatlined at extreme lows for several months while the moving-average convergence-divergence (MACD) shows a quiet divergence. That slight divergence suggests bears are losing grip and bulls are beginning to gain control. Both names also show rising trading volume, indicating buying interest at these depressed levels.
Daily charts, viewed in the context of monthly and weekly signals, also appear constructive. They suggest these stocks have at least reached a bottom and may be poised for a rebound. Indicators across timeframes are aligned and could trigger a strong buy if price action advances; if so, the current lows would be confirmed and market reversals would become higher-probability outcomes. See also market reversals.
Valuation, Analyst Sentiment, and Institutional Activity Point to Cybersecurity Rebound
Valuations remain elevated on a near-term basis—PANW trades near 40X its current-year earnings outlook and Zscaler near 36X—but those multiples price in robust growth.
The cybersecurity industry is expected to grow at roughly a 10%–15% compound annual growth rate (CAGR) over the next decade, with leaders such as Palo Alto and Zscaler growing faster than the industry average.
Analysts forecast Palo Alto to grow at a high-teens CAGR and Zscaler at a low-to-mid 20% CAGR, which makes current prices look attractive relative to long-term (2035) consensus estimates.
Under those assumptions, these stocks would trade at only about 12X and 8X their long-term forecasts—implying roughly 100% upside for PANW and nearly 200% upside for Zscaler just to align with broad market multiples as they grow into their forecasts. If they continue to command a premium, upside could be greater.
Analysts contributed to the 2025–2026 corrections by lowering price targets, which pushed current prices toward the bottom end of target ranges.
As of early March 2026, the market reaction appears overblown and value has emerged. Zscaler trades well below the low end of its target range, with consensus implying about an 85% upside; Palo Alto is nearer the low end, with consensus forecasting roughly 40% upside.
Institutional activity also supports the case for a bottom. Institutions sold heavily in Q3 2025, capping gains and driving prices down, but shifted back to buying in Q4 and early Q1 2026.
MarketBeat's data show institutions have been accumulating at a pace of more than $2 bought for every $1 sold, providing solid support and a potential tailwind as rebounds gain traction. Short interest is also notable, and MarketBeat's data indicate short-covering is underway in both names.
This email is a paid advertisement for Altimetry, a third-party advertiser of Earnings360 and MarketBeat.
This ad is sent on behalf of Altimetry, 110 Cambridge Street, Cambridge, MA 02141. If you would like to optout from receiving offers from Altimetry please click here.
If you have questions about your subscription, please don't hesitate to email MarketBeat's South Dakota based support team at contact@marketbeat.com.
If you no longer wish to receive email from Earnings360, you can unsubscribe.
© 2006-2026 MarketBeat Media, LLC. All rights protected.
345 N Reid Pl., Sixth Floor, Sioux Falls, S.D. 57103. U.S.A..
